Instituto Nacional Of Saude Dr Ricardo Jorge
Instituto Nacional Of Saude Dr Ricardo Jorge
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-2-2015 | Award Amount: 1.44M | Year: 2016
ERINHA2 aims to complete the work carried out during the first preparatory phase (PP1) - ERINHA - in order to reach the financial, administrative and technical maturity necessary to complete the establishment of the Research Infrastructre and ensure that the operation phase can begin in 2018. ERINHA2 will therefore finalise the decision to use the status of an association and prepare the necessary legal document to register the RI depending on the country voted on to host the Central Coordinating Unit. ERINHA2 will prepare all procedures and protocols (human resources, IPR, ethics) needed to effectively operate the RI. The financial and business plans prepared in ERINHA (PP1) will updated and presented to national and international stakeholders to obtain their agreement to fund the infrastructure. An overarching group of activities - WP5, Stakeholders and commitment - will aim to accompany all partner countries in their efforts to obtain agreements and funding. This WP5 will ensure all relevant stakeholders and potential users are informed of the progress, services and benefits of ERINHA. The utlimate outcome of ERINHA2 will be the signtature of the ERINHA statutes among the founding countries to officially establish the RI and enter into the construction phase.
Agency: European Commission | Branch: FP7 | Program: CP-CSA-Infra-PP | Phase: INFRA-2010-2.2.8 | Award Amount: 4.79M | Year: 2010
In the context of the emerging and re-emerging infectious diseases involving highly pathogenic microorganisms, European countries have to be well-prepared to face such threats. However, the Biosafety Level 4 (BSL4) capacity in Europe is not sufficient enough to cover the efficient development of diagnosis, prophylactic and therapeutics means against these pathogens. Moreover, there is no global coordination of activities and harmonization of practice in this field. Therefore, the ERINHA project proposes the creation of a top world-class BSL4 research infrastructure that will address the actual European capacity sparseness. The project plans to conduct five main actions which are: (i) Building additional BSL4 areas in several existing BSL4 laboratories, (ii) Building BSL4 laboratories in strategically selected EU countries that are lacking one, (iii) Building a support infrastructure around BSL4 laboratories mainly dedicated to host scientific visitors and staff, (iv) Setting-up the user access to the ERINHA infrastructure, (v) Establishing coordination capacities for efficient dispatching and control of all activities. For 46 months, the ERINHA Preparatory Phase will focus on (i) Identifying relevant sites in Europe for new BSL4 constructions or major upgrades, (ii) Getting political and financial commitments from National, European or International concerned entities to support construction, (iii) Establishing a secured and validated financial plan for construction, (iv) Defining and implementing an appropriate governance and legal framework, (v) Harmonising and disseminating common procedures related to L4 biological resources, biosafety and biosecurity management, (iv) Defining and implementing joint training programs to operate in BSL4 facilities, (vii) Identifying the ERINHAs users and establishing rules for access. These achievements will allow the ERINHA project to reach the legal, financial and technical maturity to proceed to the construction phase.
Agency: European Commission | Branch: H2020 | Program: COFUND-EJP | Phase: SC1-PM-05-2016 | Award Amount: 74.06M | Year: 2017
The overarching goal of the European Human Biomonitoring Initiative (HBM4EU) is to generate knowledge to inform the safe management of chemicals and so protect human health. We will use human biomonitoring to understand human exposure to chemicals and resulting health impacts and will communicate with policy makers to ensure that our results are exploited in the design of new chemicals policies and the evaluation of existing measures. Key objectives include: Harmonizing procedures for human biomonitoring across 26 countries, to provide policy makers with comparable data on human internal exposure to chemicals and mixtures of chemicals at EU level; Linking data on internal exposure to chemicals to aggregate external exposure and identifying exposure pathways and upstream sources. Information on exposure pathways is critical to the design of targeted policy measures to reduce exposure; Generating scientific evidence on the causal links between human exposure to chemicals and negative health outcomes; and Adapting chemical risk assessment methodologies to use human biomonitoring data and account for the contribution of multiple external exposure pathways to the total chemical body burden. We will achieve these objectives by harmonizing human biomonitoring initiatives in 26 countries, drawing on existing expertise and building new capacities. By establishing National Hubs in each country to coordinate activities, we will create a robust Human Biomonitoring Platform at European level. This initiative contributes directly to the improvement of health and well-being for all age groups, by investigating how exposure to chemicals affects the health of different groups, such as children, pregnant women, foetuses and workers. We will also investigate how factor such as behavior, lifestyle and socio-economic status influence internal exposure to chemicals across the EU population. This knowledge will support policy action to reduce chemical exposure and protect health.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRADEV-02-2016 | Award Amount: 1.96M | Year: 2017
The general objective of PRO-METROFOOD is to bring the emerging METROFOOD-RI ESFRI project to the level of maturity required for entering in the active project list, strengthening the Consortium and planning the future phases. The specific objectives have been set up in close relationship with the ESFRI SWG & IG Recommendation. 4 specific objectives have been identified: OBJ1 design strategies on the medium and long terms; OBJ2 provide the organizational framework of METROFOOD-RI; OBJ3 demonstrate the capability of METROFOOD-RI to supply scientific services and prepare the chart of services; OBJ4 establish plans to coherently integrate METROFOOD-RI into the European landscape, realising coordination with EU and National initiatives and positioning at a global level. The strategic Plan will be tailored to the Pan European Infrastructure current and envisaged capabilities, market opportunities and business needs. It will be developed by involving funding agencies, relevant authorities supporting METROFOOD-RI and other stakeholders. A management conceptual model will be developed and the framework will be designed under operational, strategic and institutional aspects. Management procedures suitable for the different phases will set up, so to cover short and long-term goals. A Quality Documentation System (QDS) will be developed and a data management plan (DMP) will be defined. In order to demonstrate the capability of PRO-METROFOOD to supply services and to test its inter-operability, pilot services will be performed. In strict accordance with the METROFOOD-RI strategies, plans to coherently integrate METROFOOD-RI into the European landscape will be developed. A Communication plan and education and training programmes will be developed for the different phases of METROFOOD-RI realization (earl, preparatory, implementation and operational phases). For each phase the main coordinator, the target group and the main training subject areas will be specified.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-04-2016 | Award Amount: 7.35M | Year: 2017
Over 130,000 children born in Europe every year will have a congenital anomaly (CA; birth defect). These CAs, which are often rare diseases, are a major cause of infant mortality, childhood morbidity and long-term disability. EUROCAT is an established European network of population-based registries for the epidemiologic surveillance of CAs. EUROlinkCAT will use the EUROCAT infrastructure to support 21 EUROCAT registries in 13 European countries to link their CA data to mortality, hospital discharge, prescription and educational databases. Each registry will send standard aggregate tables and analysis results to a Central Results Repository (CRR) thus respecting data security issues surrounding sensitive data. The CRR will contain standardised summary data and analyses on an estimated 200,000 children with a CA born from 1995 to 2014 up to age 10, enabling hypotheses on their health and education to be investigated at an EU level. This enhanced information will allow optimisation of personalised care and treatment decisions for children with rare CAs. Registries will be supported in using social media platforms to connect with families who live with CAs in their regions. A novel sustainable e-forum, ConnectEpeople, will link these families with local, national and international registries and information resources. ConnectEpeople will involve these families in setting research priorities and ensuring a meaningful dissemination of results. Findings will provide evidence to inform national treatment guidelines, such as concerning screening programs, to optimise diagnosis, prevention and treatment for these children and reduce health inequalities in Europe. An economic evaluation of the hospitalisation costs associated with CA will be provided. The CRR and associated documentation, including linkage and standardisation procedures and ConnectEpeople forum will be available post-EUROlinkCAT thus facilitating future local and EU level analyses.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: KBBE.2010.4-01 | Award Amount: 1.12M | Year: 2011
The objective is to further integrate/refine the EuroFIR Food Platform (EFP), to improve/support the ways research is undertaken into relationships between food, diets and health in Europe. Our focus is on extending application and exploitation of validated food data and tools for pan-European nutrition studies and networked usage, implementation of standards and best practice. This together forms the basis of long-term sustainability through the newly established legal entity EuroFIR AISBL). Six Work Packages are included: Quality standards & certification; Systems integration & operational support; Integration & business development; Training; Dissemination & Management. The revised consortium has 35 existing EuroFIR partners (18 as 3rd parties/EuroFIR AISBL members). The already achieved high-level institutional commitment will be further strengthened. The new General Assembly consists of executive representatives of all beneficiaries (who are also AISBL Members), thus real and durable integration is achievable. The Executive Board will work closely with EuroFIR AISBL to provide an integrated approach to joint activities and stakeholder engagements. A high-level External Advisory Board of key users/stakeholders from Europe and internationally will ensure that food data, other products and services are fine-tuned to stakeholders needs, keeping Europe at the forefront of leadership and innovation in this area. Outputs are consistent with the ETP `Food for Life and will further support Theme 2 (FP7) in food and nutrition research contributing to the structuring of the European Research Area and world-class scientific/technological excellence. Additionally, the outputs bring the EFP in alignment with the current European CEN Standard on Food Data and its application.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 7.52M | Year: 2015
The I-MOVE\ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted. Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2011.2.4-02 | Award Amount: 7.58M | Year: 2012
Total Diet Studies (TDS) allow getting information on real dietary exposure to food contaminants consumption (heavy metals, mycotoxins, POPs...) and estimating chronic exposure to pesticide residues in food and food additives intake. TDS consider total exposure from whole diets and are based on food contamination as consumed rather than contamination from raw commodities, thus ensuring a realistic exposure measure. TDS facilitate risk assessment (RA) and health monitoring (HM). Some EU Member States (MS) and Candidate Countries (CC) have no TDS programme or use various methods to collect data, which were not examined yet to tell whether they are comparable or not. This is of interest for EFSA or WHO-FAO. Similarly it is important to harmonise methods to assess dietary exposure risks in MS, CC and at the European level compared with other world regions. The methods proposed will aim for food sampling, standard analytical procedures, exposure assessment modelling, priority foods and selected chemical contaminants consistency across MS and CC. Various approaches and methods to identify sampling and analyses will be assessed and best practice defined. Contaminants and foods which contribute most to total exposure in European populations will be defined. Priority will be given to training and support in EU MS and CC currently without TDS. It will demonstrate best practice in creating a TDS programme using harmonised methods in regions previously lacking TDS, and ensure consistency of data collected. A database will be set up describing existing EU studies and collating harmonised exposure measures and designed to allow risk assessors and managers handling dietary exposure more accurately and more specifically. TDSEXPOSURE will spread excellence in TDS throughout stakeholders and establish a legacy of harmonised methods for sampling and analysis, and science-based recommendations for future global studies.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2010.2.4.4-2 | Award Amount: 2.92M | Year: 2010
Rare diseases represent an important public-health issue, affecting 26-30 million persons across Europe, and a major challenge for research. The fragmentation of resources and knowledge for the 6000-8000 rare diseases and the lack of treatment for the majority of them necessitate a coordinated European approach to unravel the underlying molecular defects and pathophysiological mechanisms. The low number of affected patients requires transnational collaboration with multidisciplinary approaches to map prevalences, build patient registries, identify biomarkers, develop new diagnostics and finally perform clinical studies for the development of treatments. The successful linking of research funding organisations in E-Rare-1 and the subsequent exemplary joint funding activities have attested the need of, and the acknowledgment from, the research community for transnational funding of collaborative, multidisciplinary and ambitious projects on rare diseases. It has leveraged funding for rare disease research in countries without specific programmes for rare diseases and thus enabled the participation of researchers in these countries to transnational projects. The E-Rare-2 project aims at deepening and extending the cooperation among the E-Rare-1 and the five new partners by systematic exchange of information, yearly launching of joint calls, thorough assessment of the funding mechanisms and results of the funded research projects and, finally, strategic activities aiming at a sustainable development and extension of the network. Special attention will be given to the outreach and knowledge exchange with new member states, countries outside of Europe and key stakeholders/initiatives important for rare diseases. E-Rare-2 activities will thus further contribute to reducing fragmentation of research and resources through the enhanced coordination and transnational funding of excellent research on rare diseases, thereby shaping the European Research Area for rare diseases.